Moreover, SAC inactivation is common in BRCA2-deficient prostate cancer patients and many BRCA2-deficient cell lines, and PP2A inhibitors (PP2Ais) that can restore SAC activity are potential drugs for the synthetic lethality of BRCA2-mutated cancer cells. Here, ADCY10 is linked to prostate cancer.